The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone

Hematology/ Oncology and Stem Cell Therapy

Volumn 7, Issue 1, 2014, Pages 1-17

  Afreen, Sehar ^a   Dermime, Said ^a  

^a KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

B7 H1; Cancer prognosis; CD 274; Immune escape; PD L1; Targeted therapy

Indexed keywords

BMS 936559; CISPLATIN; CYTARABINE; DAUNORUBICIN; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; GAMMA INTERFERON; HONOKIOL; MELOXICAM; MONOCLONAL ANTIBODY; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PEPTIDE DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; SINOMENINE; SMALL INTERFERING RNA; TRIPTOLIDE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; BILE DUCT CARCINOMA; BREAST CANCER; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLON CANCER; CUTANEOUS T CELL LYMPHOMA; CYSTECTOMY; DRUG POTENTIATION; DRUG TARGETING; ESOPHAGUS CANCER; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOREGULATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NEPHROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; PNEUMONIA; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOMA; THYMOMA; TUMOR ESCAPE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT TUMOR; UTERINE CERVIX CARCINOMA;

B7-H1; CANCER PROGNOSIS; CD 274; IMMUNE ESCAPE; PD-L1; TARGETED THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNITY; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84896713991     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hemonc.2013.09.005     Document Type: Review

References (194)

1. S. Dermime, D.E. Gilham, D.M. Shaw, E.J. Davidson, el-K. Meziane, and A. Armstrong et al. Vaccine and antibody-directed T cell tumour immunotherapy Biochim Biophys Acta 1704 1 2004 11 35
2. M.D. Vesely, and R.D. Schreiber Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy Ann N Y Acad Sci 1284 2013 1 5
3. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 19 2002 12293 12297
4. H. Ghebeh, S. Mohammed, A. Al-Omair, A. Qattan, C. Lehe, and G. Al-Qudaihi et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors Neoplasia 8 3 2006 190 198
5. H. Ghebeh, A. Tulbah, S. Mohammed, N. Elkum, S.M. Bin Amer, and T. Al-Tweigeri et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells Int J Cancer 121 4 2007 751 758
6. H. Ghebeh, E. Barhoush, A. Tulbah, N. Elkum, T. Al-Tweigeri, and S. Dermime FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy BMC Cancer 23 8 2008 57
7. H. Ghebeh, C. Lehe, E. Barhoush, K. Al-Romaih, A. Tulbah, and M. Al-Alwan et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule Breast Cancer Res 12 4 2010 R48
8. J.A. Brown, D.M. Dorfman, F.R. Ma, E.L. Sullivan, O. Munoz, and C.R. Wood et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J Immunol 170 3 2003 1257 1266
9. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, and D.B. Flies et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 8 2002 793 800
10. T.J. Curiel, S. Wei, H. Dong, X. Alvarez, P. Cheng, and P. Mottram et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat Med 9 5 2003 562 567
11. J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, and K. Yamaguchi et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 9 2007 3360 3365
12. R. Karim, E.S. Jordanova, S.J. Piersma, G.G. Kenter, L. Chen, and J.M. Boer et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma Clin Cancer Res 15 20 2009 6341 6347
13. Y.A. Cho, H.J. Yoon, J.I. Lee, S.P. Hong, and S.D. Hong Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma Oral Oncol 47 12 2011 1148 1153
14. T.S. Malaspina, T.H. Gasparoto, M.R. Costa, E.F. de Melo, M.R. Ikoma Jr., and J.H. Damante et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma Cancer Immunol Immunother 60 7 2011 965 974
15. F. Tsushima, K. Tanaka, N. Otsuki, P. Youngnak, H. Iwai, and K. Omura et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma Oral Oncol 42 3 2006 268 274
16. S. Lyford-Pike, S. Peng, G.D. Young, J.M. Taube, W.H. Westra, and B. Akpeng et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma Cancer Res 73 6 2013 1733 1741
17. S.E. Strome, H. Dong, H. Tamura, S.G. Voss, D.B. Flies, and K. Tamada et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res 63 19 2003 6501 6505
18. T. Avril, S. Saikali, E. Vauleon, A. Jary, A. Hamlat, and M. De Tayrac et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions J Neuroimmunol 225 1-2 2010 22 33
19. J.F. Jacobs, A.J. Idema, K.F. Bol, S. Nierkens, O.M. Grauer, and P. Wesseling et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors Neuro Oncol 11 4 2009 394 402
20. R. Wilmotte, K. Burkhardt, V. Kindler, M.C. Belkouch, G. Dussex, and N. Tribolet et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion Neuroreport 16 10 2005 1081 1085
21. S. Wintterle, B. Schreiner, M. Mitsdoerffer, D. Schneider, L. Chen, and R. Meyermann et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis Cancer Res 63 21 2003 7462 7467
22. Y. Yao, R. Tao, X. Wang, Y. Wang, Y. Mao, and L.F. Zhou B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells Neuro Oncol 11 6 2009 757 766
23. J.M. Boland, E.D. Kwon, S.M. Harrington, J.A. Wampfler, H. Tang, and P. Yang et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung Clin Lung Cancer 14 2 2013 157 163
24. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 15 2004 5094 5100
25. C.Y. Mu, J.A. Huang, Y. Chen, C. Chen, and X.G. Zhang High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 3 2011 682 688
26. M.C. Hsu, J.R. Hsiao, K.C. Chang, Y.H. Wu, I.J. Su, and Y.T. Jin et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma Mod Pathol 23 10 2010 1393 1403
27. F. Zhang, Z. Liu, Y. Cui, G. Wang, and P. Cao The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22 9 2008 408 410 [in Chinese]
28. M. Loos, R. Langer, T. Schuster, R. Gertler, A. Walch, and S. Rauser et al. Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma Ann Thorac Surg 91 4 2011 1025 1031
29. Y. Ohigashi, M. Sho, Y. Yamada, Y. Tsurui, K. Hamada, and N. Ikeda et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 11 8 2005 2947 2953
30. C. Wu, Y. Zhu, J. Jiang, J. Zhao, X.G. Zhang, and N. Xu Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance Acta Histochem 108 1 2006 19 24
31. J. Chen, G. Li, H. Meng, Y. Fan, Y. Song, and S. Wang et al. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas Cancer Immunol Immunother 61 1 2012 101 108
32. Q. Gao, X.Y. Wang, S.J. Qiu, I. Yamato, M. Sho, and Y. Nakajima et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 3 2009 971 979
33. L. Geng, J. Deng, G. Jiang, P. Song, Z. Wang, and Z. Jiang et al. B7-H1 up-regulated expression in human hepatocellular carcinoma tissue: correlation with tumor interleukin-10 levels Hepatogastroenterology 58 107-108 2011 960 964
34. B.J. Wang, J.J. Bao, J.Z. Wang, Y. Wang, M. Jiang, and M.Y. Xing et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma World J Gastroenterol 17 28 2011 3322 3329
35. K. Wu, I. Kryczek, L. Chen, W. Zou, and T.H. Welling Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions Cancer Res 69 20 2009 8067 8075
36. Y. Ye, L. Zhou, X. Xie, G. Jiang, H. Xie, and S. Zheng Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion J Surg Oncol 100 6 2009 500 504
37. D. Hua, J. Sun, Y. Mao, L.J. Chen, Y.Y. Wu, and X.G. Zhang B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma World J Gastroenterol 18 9 2012 971 978
38. J.X. Xiao, P.S. Bai, B.C. Lai, L. Li, J. Zhu, and Y.L. Wang B7 molecule mRNA expression in colorectal carcinoma World J Gastroenterol 11 36 2005 5655 5658
39. X.L. Chen, S.X. Yuan, C. Chen, Y.X. Mao, G. Xu, and X.Y. Wang Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance Ai Zheng 28 12 2009 1328 1332 [in Chinese]
40. L. Geng, D. Huang, J. Liu, Y. Qian, J. Deng, and D. Li et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression J Cancer Res Clin Oncol 134 9 2008 1021 1027
41. D.S. Huang, J.W. Liu, L. Geng, G.P. Jiang, G.L. Shen, and W.F. Yao Role of B7-H1 in pancreatic carcinoma immune evasion Zhonghua Wai Ke Za Zhi 47 4 2009 282 285
42. M. Loos, N.A. Giese, J. Kleeff, T. Giese, M.M. Gaida, and F. Bergmann et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer Cancer Lett 268 1 2008 98 109
43. T. Nomi, M. Sho, T. Akahori, K. Hamada, A. Kubo, and H. Kanehiro et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clin Cancer Res 13 7 2007 2151 2157
44. L. Wang, Q. Ma, X. Chen, K. Guo, J. Li, and M. Zhang Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma World J Surg 34 5 2010 1059 1065
45. C. Blank, J. Kuball, S. Voelkl, H. Wiendl, B. Becker, and B. Walter et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro Int J Cancer 119 2 2006 317 327
46. A.E. Krambeck, H. Dong, R.H. Thompson, S.M. Kuntz, C.M. Lohse, and B.C. Leibovich et al. Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma Clin Cancer Res 13 6 2007 1749 1756
47. R.H. Thompson, M.D. Gillett, J.C. Cheville, C.M. Lohse, H. Dong, and W.S. Webster et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 49 2004 17174 17179
48. R.H. Thompson, M.D. Gillett, J.C. Cheville, C.M. Lohse, H. Dong, and W.S. Webster et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma Cancer 104 10 2005 2084 2091
49. R.H. Thompson, S.M. Kuntz, B.C. Leibovich, H. Dong, C.M. Lohse, and W.S. Webster et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 7 2006 3381 3385
50. R.H. Thompson, H. Dong, and E.D. Kwon Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy Clin Cancer Res 13 2 Pt 2 2007 709s 715s
51. S.A. Boorjian, Y. Sheinin, P.L. Crispen, S.A. Farmer, C.M. Lohse, and S.M. Kuntz et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival Clin Cancer Res 14 15 2008 4800 4808
52. B.A. Inman, T.J. Sebo, X. Frigola, H. Dong, E.J. Bergstralh, and I. Frank et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression Cancer 109 8 2007 1499 1505
53. J. Nakanishi, Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunol Immunother 56 8 2007 1173 1182
54. J. Gadiot, A.I. Hooijkaas, A.D. Kaiser, H. van Tinteren, H. van Boven, and C. Blank Overall survival and PD-L1 expression in metastasized malignant melanoma Cancer 117 10 2011 2192 2201
55. R. Hino, K. Kabashima, Y. Kato, H. Yagi, M. Nakamura, and T. Honjo et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 116 7 2010 1757 1766
56. J.M. Taube, R.A. Anders, G.D. Young, H. Xu, R. Sharma, and T.L. McMiller et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 127 2012 127ra37
57. H. Li, C. Wang, G. Guo, C. Gao, Y. Wu, and Y. Chen The characteristic expression of B7-associated proteins in Langerhans cell sarcoma Acta Histochem 114 7 2012 733 743
58. T. Kozako, M. Yoshimitsu, H. Fujiwara, I. Masamoto, S. Horai, and Y. White et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients Leukemia 23 2 2009 375 382
59. R.A. Wilcox, A.L. Feldman, D.A. Wada, Z.Z. Yang, N.I. Comfere, and H. Dong et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders Blood 114 10 2009 2149 2158
60. H.R. Salih, S. Wintterle, M. Krusch, A. Kroner, Y.H. Huang, and L. Chen et al. The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans Exp Hematol 34 7 2006 888 894
61. X. Li, Y.F. Wang, W. Ge, Z.J. Li, Z. Yu, and Y.T. Li et al. Real-time quantitative PCR detecting B7-H1 gene expression in leukemia cells and its clinical implications Zhonghua Xue Ye Xue Za Zhi 28 12 2007 837 840 [in Chinese]
62. X. Chen, S. Liu, L. Wang, W. Zhang, Y. Ji, and X. Ma Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia Cancer Biol Ther 7 5 2008 622 627
63. X. Li, W.J. Sun, Y. Xu, Z.J. Li, Z. Yu, and S.H. Deng et al. Expression of B7-H1 gene in leukemia cells and its clinical significance Zhongguo Shi Yan Xue Ye Xue Za Zhi 20 3 2012 541 544 in Chinese]
64. W. Ge, X. Ma, X. Li, Y. Wang, C. Li, and H. Meng et al. B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells Leuk Res 33 7 2009 948 957
65. C. Berthon, V. Driss, J. Liu, K. Kuranda, X. Leleu, and N. Jouy et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors Cancer Immunol Immunother 59 12 2010 1839 1849
66. W.J. Norde, F. Maas, W. Hobo, A. Korman, M. Quigley, and M.G. Kester et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation Cancer Res 71 15 2011 5111 5122
67. W.J. Sun, and X. Li B7-H1, a prognostic factor for patient's response to therapy of acute myeloid leukemia Zhongguo Shi Yan Xue Ye Xue Za Zhi 20 6 2012 1332 1335
68. M. Grzywnowicz, J. Zaleska, D. Mertens, W. Tomczak, P. Wlasiuk, and K. Kosior et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia PLoS ONE 7 4 2012 e35178
69. W.H. Hallett, W. Jing, W.R. Drobyski, and B.D. Johnson Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade Biol Blood Marrow Transplant 17 8 2011 1133 1145
70. H. Tamura, M. Ishibashi, T. Yamashita, S. Tanosaki, N. Okuyama, and A. Kondo et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma Leukemia 27 2 2013 464 472
71. C. Blank, T.F. Gajewski, and A. Mackensen Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy Cancer Immunol Immunother 54 4 2005 307 314
72. J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, and D. Hetuin et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood 110 1 2007 296 304
73. F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, and M. Ichikawa et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 3 2005 1089 1096
74. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward et al. Cancer statistics, 2004 CA Cancer J Clin 54 1 2004 8 29
75. Breast Cancer Facts and Figures 2003-2004. American Cancer Society. Available at: < http://www.cancer.org/acs/groups/content/@nho/documents/ document/caff2003brfpwsecuredpdf.pdf >; 2004 [accessed 05/06, 2013].
76. A. Hasan, H. Ghebeh, C. Lehe, R. Ahmad, and S. Dermime Therapeutic targeting of B7-H1 in breast cancer Expert Opin Ther Targets 15 10 2011 1211 1225
77. H. zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat Rev Cancer 2 5 2002 342 350
78. F.X. Bosch, M.M. Manos, N. Muñoz, M. Sherman, A.M. Jansen, and J. Peto et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group J Natl Cancer Inst 87 11 1995 796 802
79. M. Nakagawa, D.P. Stites, S. Patel, S. Farhat, M. Scott, and N.K. Hills et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens J Infect Dis 182 2 2000 595 598
80. M.J. Welters, A. de Jong, S.J. van den Eeden, J.M. van der Hulst, K.M. Kwappenberg, and S. Hassane et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter Cancer Res 63 3 2003 636 641
81. A. de Jong, M.I. van Poelgeest, J.M. van der Hulst, J.W. Drijfhout, G.J. Fleuren, and C.J. Melief et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6 Cancer Res 64 15 2004 5449 5455
82. F. Peyrade, D. Cupissol, L. Geoffrois, F. Rolland, C. Borel, and C. Ciais et al. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes Oral Oncol 49 6 2013 482 491
83. Y. Li, X. Shi, X. Rong, Y. Peng, and Y. Tang Neurosurgery and prognosis in patients with radiation-induced brain injury after nasopharyngeal carcinoma radiotherapy: a follow-up study Radiat Oncol 11 8 2013 88
84. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
85. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics, 2007 CA Cancer J Clin 57 1 2007 43 66
86. Y. Wang, Q. Zhuang, S. Zhou, Z. Hu, and R. Lan Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance J Huazhong Univ Sci Technolog Med Sci 29 1 2009 77 79
87. H.I. Wettersten, and R.H. Weiss Potential biofluid markers and treatment targets for renal cell carcinoma Nat Rev Urol 10 6 2013 336 344
88. D.M. Green, G.J. D'Angio, J.B. Beckwith, N.E. Breslow, P.E. Grundy, and M.L. Ritchey et al. Wilms tumor CA Cancer J Clin 46 1 1996 46 63
89. J.C. Routh, R.A. Ashley, T.J. Sebo, C.M. Lohse, D.A. Husmann, and S.A. Kramer et al. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence J Urol 179 5 2008 1954 1959 [discussion 1959-60]
90. A. Slipicevic, and M. Herlyn Narrowing the knowledge gaps for melanoma Ups J Med Sci 117 2 2012 237 243
91. H. Tsao, M.B. Atkins, and A.J. Sober Management of cutaneous melanoma N Engl J Med 351 10 2004 998 1012
92. C.R. Thomas, C.D. Wright, and P.J. Loehrer Thymoma: state of the art J Clin Oncol 17 7 1999 2280 2289
93. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, et al. SEER cancer statistics review, 1975-2009. Available at: < http://seer.cancer.gov/csr/1975-2010/ >; 2009 [accessed 04/17, 2013].
94. V. Kumar, and S.L. Robbins Robbins basic pathology 8th ed. 2007 Saunders/Elsevier Philadelphia
95. C. Delfino, V. Grandi, A. Pileri, S. Rupoli, P. Quaglino, and R. Alterini et al. Combination treatment in CTCL: the current role of bexarotene G Ital Dermatol Venereol 147 6 2012 573 580
96. J. Yodoi, K. Takatsuki, and T. Masuda Letter: two cases of T-cell chronic lymphocytic leukemia in Japan N Engl J Med 290 10 1974 572 573
97. L. Tamás, E. Sári, G. Répássy, P. Szabó, E. Bagdi, and L. Krenács et al. Spontaneous remission in localized diffuse large B-cell lymphoma Pathol Oncol Res 17 3 2011 779 784
98. D.J. Andorsky, R.E. Yamada, J. Said, G.S. Pinkus, D.J. Betting, and J.M. Timmerman Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells Clin Cancer Res 17 13 2011 4232 4244
99. Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJL. Cancer incidence, mortality and survival by site for 14 regions of the world. Available at: http://www.who.int/healthinfo/paper13.pdf >; 2001 [accessed 04/21/2013].
100. C.D. Collins Problems monitoring response in multiple myeloma Cancer Imaging 5 Spec No. A 2005 S119 S126
101. H. Kuipers, F. Muskens, M. Willart, D. Hijdra, F.B. van Assema, and A.J. Coyle et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation Eur J Immunol 36 9 2006 2472 2482
102. A. Nakazawa, I. Dotan, J. Brimnes, M. Allez, L. Shao, and F. Tsushima et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells Gastroenterology 126 5 2004 1347 1357
103. D. Yadav, and N. Sarvetnick Costimulation and pancreatic autoimmunity: the PD-1/PD-L conundrum Rev Diabet Stud 3 1 2006 6 10
104. Y. Chen, J. Li, J. Zhang, T. Zhao, L. Zou, and Y. Tang et al. Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells Int Immunopharmacol 5 9 2005 1446 1457
105. J. Hori, M. Wang, M. Miyashita, K. Tanemoto, H. Takahashi, and T. Takemori et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts J Immunol 177 9 2006 5928 5935
106. G. Raimondi, W.J. Shufesky, D. Tokita, A.E. Morelli, and A.W. Thomson Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells J Immunol 176 5 2006 2808 2816
107. D. Bell, P. Chomarat, D. Broyles, G. Netto, G.M. Harb, and S. Lebecque et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas J Exp Med 190 10 1999 1417 1426
108. M.B. Lutz, and C. Kurts Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells Eur J Immunol 39 9 2009 2325 2330
109. B.A. Inman, X. Frigola, H. Dong, and E.D. Kwon Costimulation, coinhibition and cancer Curr Cancer Drug Targets 7 1 2007 15 30
110. R.J. Greenwald, G.J. Freeman, and A.H. Sharpe The B7 family revisited Annu Rev Immunol 23 2005 515 548
111. D.J. Lenschow, T.L. Walunas, and J.A. Bluestone CD28/B7 system of T cell costimulation Annu Rev Immunol 14 1996 233 258
112. S. Dermime, and M.D. Aljurf Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma Leuk Lymphoma 46 4 2005 497 507
113. B. Salomon, and J.A. Bluestone Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation Annu Rev Immunol 19 2001 225 252
114. J. Foell, B. Hewes, and R.S. Mittler T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity Curr Cancer Drug Targets 7 1 2007 55 70
115. K.A. Hofmeyer, H. Jeon, and X. Zang The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion J Biomed Biotechnol 2011 2011 451694
116. J.M. Chemnitz, R.V. Parry, K.E. Nichols, C.H. June, and J.L. Riley SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation J Immunol 173 2 2004 945 954
117. B.T. Fife, K.E. Pauken, T.N. Eagar, T. Obu, J. Wu, and Q. Tang et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal Nat Immunol 10 11 2009 1185 1192
118. G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, and H. Nishimura et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 7 2000 1027 1034
119. L. Carter, L.A. Fouser, J. Jussif, L. Fitz, B. Deng, and C.R. Wood et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2 Eur J Immunol 32 3 2002 634 643
120. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 5609 2003 1057 1061
121. W.F. Ng, P.J. Duggan, F. Ponchel, G. Matarese, G. Lombardi, and A.D. Edwards et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells Blood 98 9 2001 2736 2744
122. A.M. Thornton, and E.M. Shevach CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production J Exp Med 188 2 1998 287 296
123. S. Liang, P. Alard, Y. Zhao, S. Parnell, S.L. Clark, and M.M. Kosiewicz Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus J Exp Med 201 1 2005 127 137
124. Y. Kitazawa, M. Fujino, Q. Wang, H. Kimura, M. Azuma, and M. Kubo et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses Transplantation 83 6 2007 774 782
125. S. Amarnath, C.W. Mangus, J.C. Wang, F. Wei, A. He, and V. Kapoor et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells Sci Transl Med 3 111 2011 111ra120
126. H. Dong, and X. Chen Immunoregulatory role of B7-H1 in chronicity of inflammatory responses Cell Mol Immunol 3 3 2006 179 187
127. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, and G. Regnani et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 3 2003 203 213
128. S. Ishigami, S. Natsugoe, K. Tokuda, A. Nakajo, C. Xiangming, and H. Iwashige et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer Cancer Lett 159 1 2000 103 108
129. W.S. Webster, C.M. Lohse, R.H. Thompson, H. Dong, X. Frigola, and D.L. Dicks et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival Cancer 107 1 2006 46 53
130. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 4 2012 252 264
131. C.A. Crane, A. Panner, J.C. Murray, S.P. Wilson, H. Xu, and L. Chen et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer Oncogene 28 2 2009 306 312
132. C. Crane, A. Panner, R.O. Pieper, J. Arbiser, and A.T. Parsa Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function J Immunother 32 6 2009 585 592
133. M. Marzec, Q. Zhang, A. Goradia, P.N. Raghunath, X. Liu, and M. Paessler et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) Proc Natl Acad Sci U S A 105 52 2008 20852 20857
134. T. Yamazaki, H. Akiba, H. Iwai, H. Matsuda, M. Aoki, and Y. Tanno et al. Expression of programmed death 1 ligands by murine T cells and APC J Immunol 169 10 2002 5538 5545
135. P. Loke, and J.P. Allison PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells Proc Natl Acad Sci U S A 100 9 2003 5336 5341
136. J. Kim, A.C. Myers, L. Chen, D.M. Pardoll, Q.A. Truong-Tran, and A.P. Lane et al. Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells Am J Respir Cell Mol Biol 33 3 2005 280 289
137. S.K. Lee, S.H. Seo, B.S. Kim, C.D. Kim, J.H. Lee, and J.S. Kang et al. IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells J Dermatol Sci 40 2 2005 95 103
138. C.M. Wilke, S. Wei, L. Wang, I. Kryczek, J. Kao, and W. Zou Dual biological effects of the cytokines interleukin-10 and interferon-γ Cancer Immunol Immunother 60 11 2011 1529 1541
139. M. Oelke, U. Moehrle, J.L. Chen, D. Behringer, V. Cerundolo, and A. Lindemann et al. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy Clin Cancer Res 6 5 2000 1997 2005
140. B.M. Carreno, and M. Collins BTLA: a new inhibitory receptor with a B7-like ligand Trends Immunol 24 10 2003 524 527
141. S.J. Lee, B.C. Jang, S.W. Lee, Y.I. Yang, S.I. Suh, and Y.M. Park et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274) FEBS Lett 580 3 2006 755 762
142. C. Saint-Ruf, K. Ungewiss, M. Groettrup, L. Bruno, H.J. Fehling, and H. von Boehmer Analysis and expression of a cloned pre-T cell receptor gene. Science. 1994. 266: 1208-1212 J Immunol 182 9 2009 5165 5169
143. H. Wiendl, M. Mitsdoerffer, D. Schneider, L. Chen, H. Lochmüller, and A. Melms et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies FASEB J 17 13 2003 1892 1894
144. I. Mellman, and W.J. Nelson Coordinated protein sorting, targeting and distribution in polarized cells Nat Rev Mol Cell Biol 9 11 2008 833 845
145. D.S. Chen, B.A. Irving, and F.S. Hodi Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1 Clin Cancer Res 18 24 2012 6580 6587
146. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, and P. Hwu et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
147. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
148. O. Akbari, P. Stock, A.K. Singh, V. Lombardi, W.L. Lee, and G.J. Freeman et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions Mucosal Immunol 3 1 2010 81 91
149. S. Huber, R. Hoffmann, F. Muskens, and D. Voehringer Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2 Blood 116 17 2010 3311 3320
150. H. Qiu, S. Liu, C. Xie, J. Long, and Z. Feng Regulating immunity and inhibiting tumor growth by the recombinant peptide sPD-1-CH50 Anticancer Res 29 12 2009 5089 5094
151. I. Martínez-Lacaci, P. García Morales, J.L. Soto, and M. Saceda Tumour cells resistance in cancer therapy Clin Transl Oncol 9 1 2007 13 20
152. L. Apetoh, G. Mignot, T. Panaretakis, G. Kroemer, and L. Zitvogel Immunogenicity of anthracyclines: moving towards more personalized medicine Trends Mol Med 14 4 2008 141 151
153. M. Liang, and J. Fu Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells Cancer Lett 270 2 2008 337 341
154. Early Breast Cancer Trialist's Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717.
155. C. Fermé, H. Eghbali, J.H. Meerwaldt, C. Rieux, J. Bosq, and F. Berger et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease N Engl J Med 357 19 2007 1916 1927
156. K. Tsukasaki, A. Utsunomiya, H. Fukuda, T. Shibata, T. Fukushima, and Y. Takatsuka et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801 J Clin Oncol 25 34 2007 5458 5464
157. M.J. Ehrke, K. Ryoyama, and S.A. Cohen Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture Cancer Res 44 6 1984 2497 2504
158. D.L. Maccubbin, K.R. Wing, K.F. Mace, R.L. Ho, M.J. Ehrke, and E. Mihich Adriamycin-induced modulation of host defenses in tumor-bearing mice Cancer Res 52 13 1992 3572 3576
159. J.S. Haskill Adriamycin-activated macrophages as tumor growth inhibitors Cancer Res 41 10 1981 3852 3856
160. H. Yamasaki Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum Acta Med Okayama 30 1 1976 1 20
161. L. Liu, J. Riese, K. Resch, and V. Kaever Impairment of macrophage eicosanoid and nitric oxide production by an alkaloid from Sinomenium acutum Arzneimittelforschung 44 11 1994 1223 1226
162. L. Liu, E. Buchner, D. Beitze, C.B. Schmidt-Weber, V. Kaever, and F. Emmrich et al. Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine Int J Immunopharmacol 18 10 1996 529 543
163. Y.B. Dai, H.X. Liu, and L.I. Zao Immunosuppressive effect of Sinomenine on ICAM-1 expression in rat renal allograft rejection Mod J Integr Tradit Chin West Med 12 2003 1358 1361
164. P. Yang, L. Yang, and Z. Luo Effects of Sinomenine on T lymphocyte subsets in rat renal allograft transplantation model J Clin Urol 10 2003 620 622
165. Y. Kondo, F. Takano, K. Yoshida, and H. Hojo Protection by sinomenine against endotoxin-induced fulminant hepatitis in galactosamine-sensitized mice Biochem Pharmacol 48 5 1994 1050 1052
166. A. Peng, Y. Gu, and S.Y. Lin Herbal treatment for renal diseases Ann Acad Med Singapore 34 1 2005 44 51
167. H. Yao, J. Zhou, D. Li, N. Wu, A. Bader, and S. Höxtermann et al. FK506 enhances triptolide-induced down-regulation of cyclooxygenase-2, inducible nitric oxide synthase as well as their products PGE2 and NO in TNF-alpha-stimulated synovial fibroblasts from rheumatoid arthritic patients Eur J Med Res 10 3 2005 110 116
168. W.T. Chang, J.J. Kang, K.Y. Lee, K. Wei, E. Anderson, and S. Gotmare et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway J Biol Chem 276 3 2001 2221 2227
169. X.H. Jiang, B.C. Wong, M.C. Lin, G.H. Zhu, H.F. Kung, and S.H. Jiang et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells Oncogene 20 55 2001 8009 8018
170. T. Tengchaisri, R. Chawengkirttikul, N. Rachaphaew, V. Reutrakul, R. Sangsuwan, and S. Sirisinha Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters Cancer Lett 133 2 1998 169 175
171. K.Y. Lee, W. Chang, D. Qiu, P.N. Kao, and G.D. Rosen PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells J Biol Chem 274 19 1999 13451 13455
172. S. Frese, F. Pirnia, D. Miescher, S. Krajewski, M.M. Borner, and J.C. Reed et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2 Oncogene 22 35 2003 5427 5435
173. J.M. Fidler, K. Li, C. Chung, K. Wei, J.A. Ross, and M. Gao et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy Mol Cancer Ther 2 9 2003 855 862
174. Y. Chen, J. Zhang, J. Li, T. Zhao, L. Zou, and Y. Tang et al. Triptolide inhibits B7-H1 expression on proinflammatory factor activated renal tubular epithelial cells by decreasing NF-kappaB transcription Mol Immunol 43 8 2006 1088 1098
175. T. Singh, and S.K. Katiyar Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2 Int J Oncol 38 3 2011 769 776
176. H. Liu, C. Zang, A. Emde, M.D. Planas-Silva, M. Rosche, and A. Kühnl et al. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer Eur J Pharmacol 591 1-3 2008 43 51
177. S.H. Liu, K.B. Wang, K.H. Lan, W.J. Lee, H.C. Pan, and S.M. Wu et al. Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice PLoS ONE 7 8 2012 e43711
178. M.L. Sheu, S.H. Liu, and K.H. Lan Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth PLoS ONE 2 10 2007 e1096
179. S. Ponnurangam, J.M. Mammen, S. Ramalingam, Z. He, Y. Zhang, and S. Umar et al. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells Mol Cancer Ther 11 4 2012 963 972
180. Z. He, D. Subramaniam, S. Ramalingam, A. Dhar, R.G. Postier, and S. Umar et al. Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects Am J Physiol Gastrointest Liver Physiol 301 5 2011 G929 G937
181. S. Arora, A. Bhardwaj, S.K. Srivastava, S. Singh, S. McClellan, and B. Wang et al. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells PLoS ONE 6 6 2011 e21573
182. R.F. Guillermo, C. Chilampalli, X. Zhang, D. Zeman, H. Fahmy, and C. Dwivedi Time and dose-response effects of honokiol on UVB-induced skin cancer development Drug Discov Ther 6 3 2012 140 146
183. K. Subbaramaiah, and A.J. Dannenberg Cyclooxygenase 2: a molecular target for cancer prevention and treatment Trends Pharmacol Sci 24 2 2003 96 102
184. D. Foderà, N. D'Alessandro, A. Cusimano, P. Poma, M. Notarbartolo, and N. Lampiasi et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors Ann N Y Acad Sci 1028 2004 440 449
185. T. Hida, K. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, and T. Mitsudomi et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines Clin Cancer Res 6 5 2000 2006 2011
186. M. Fukutake, S. Nakatsugi, T. Isoi, M. Takahashi, T. Ohta, and S. Mamiya et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice Carcinogenesis 19 11 1998 1939 1942
187. K.T. Nam, K.B. Hahm, S.Y. Oh, M. Yeo, S.U. Han, and B. Ahn et al. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model Clin Cancer Res 10 23 2004 8105 8113
188. M.S. Shaik, A. Chatterjee, and M. Singh Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma Clin Cancer Res 10 4 2004 1521 1529
189. B.M. Deasy, G. O'Sullivan-Coyne, T.R. O'Donovan, S.L. McKenna, and G.C. O'Sullivan Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms Cancer Lett 256 2 2007 246 258
190. S. Han, and J. Roman COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals Lung Cancer 51 3 2006 283 296
191. M. Liang, H. Yang, and J. Fu Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms Cancer Lett 276 1 2009 47 52
192. K. Iwamura, T. Kato, Y. Miyahara, H. Naota, J. Mineno, and H. Ikeda et al. SiRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions Gene Ther 19 10 2012 959 966
193. W. Hobo, T.I. Novobrantseva, H. Fredrix, J. Wong, S. Milstein, and H. Epstein-Barash et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation Cancer Immunol Immunother 62 2 2013 285 297
194. W. Hobo, F. Maas, N. Adisty, T. de Witte, N. Schaap, and R. van der Voort et al. SiRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells Blood 116 22 2010 4501 4511